In Tuesday’s Wall Street session, Sarepta Therapeutics Inc (NASDAQ:SRPT) shares traded at $61.91, down -2.99% from the previous session.
SRPT stock price is now -38.49% away from the 50-day moving average and -49.73% away from the 200-day moving average. The market capitalization of the company currently stands at $6.01B.
With the price target reduced from $161 to $87, RBC Capital Mkts Downgraded its rating from Outperform to Sector Perform for Sarepta Therapeutics Inc (NASDAQ: SRPT). On February 11, 2025, Deutsche Bank recently initiated its ‘Hold’ rating on the stock quoting a target price of $136, while ‘Needham’ rates the stock as ‘Buy’
In other news, Nicaise Claude, Director sold 2,491 shares of the company’s stock on Mar 12 ’25. The stock was sold for $248,203 at an average price of $99.64. Upon completion of the transaction, the Director now directly owns 27,812 shares in the company, valued at $1.72 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 12 ’25, Director Nicaise Claude bought 2,491 shares of the business’s stock. A total of $248,226 was incurred on buying the stock at an average price of $99.65. A total of 6.07% of the company’s stock is owned by insiders.
During the past 12 months, Sarepta Therapeutics Inc has had a low of $62.50 and a high of $173.25. As of last week, the company has a debt-to-equity ratio of 0.88, a current ratio of 4.20, and a quick ratio of 3.18. According to the stock market information, the enterprise value for the company is $5995333632, which is based on a 25.97 price-to-earnings ratio, a 0.29 price-to-earnings-growth ratio, and a beta of 0.92. The fifty day moving average price for SRPT is $100.6514 and a two-hundred day moving average price translates $123.15085 for the stock.
The latest earnings results from Sarepta Therapeutics Inc (NASDAQ: SRPT) was released for 2024-12-31. The net profit margin was 12.37% and return on equity was 19.71% for SRPT. The company reported revenue of $658.41 million for the quarter, compared to $396.78 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 65.94 percent.
